Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

NCT01427257 ·Status: COMPLETED ·Phase: PHASE1

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

NCT00405015 ·Status: COMPLETED ·Phase: PHASE2

Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease

NCT01574820 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes

NCT03560271 ·Status: COMPLETED ·Phase: PHASE2

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone

NCT00525330 ·Status: COMPLETED ·Phase: PHASE2

Effects of Pioglitazone on Platelet Function

NCT00861341 ·Status: COMPLETED ·Phase: PHASE2

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

NCT00478322 ·Status: COMPLETED ·Phase: PHASE2

Rosiglitazone to Reverse Metabolic Defects in Diabetes

NCT00094796 ·Status: COMPLETED ·Phase: PHASE2

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

NCT00513214 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

NCT01150981 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

NCT02222350 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

NCT02164266 ·Status: COMPLETED ·Phase: PHASE1

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

NCT00770367 ·Status: COMPLETED ·Phase: PHASE4

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

NCT02183350 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes

NCT01282970 ·Status: COMPLETED ·Phase: PHASE1

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT05158244 ·Status: COMPLETED ·Phase: PHASE1

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

NCT00330200 ·Status: TERMINATED ·Phase: PHASE2

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

NCT00057317 ·Status: COMPLETED ·Phase: PHASE2

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

NCT00329225 ·Status: COMPLETED ·Phase: PHASE4

Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus

NCT00232362 ·Status: WITHDRAWN ·Phase: PHASE1

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

NCT03081598 ·Status: TERMINATED ·Phase: PHASE2

Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes

NCT00306644 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy

NCT00515632 ·Status: COMPLETED ·Phase: PHASE3

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

NCT01640873 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01407003 ·Status: COMPLETED ·Phase: PHASE1/PHASE2